Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine-Reference-Cited by-同舟云学术

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine

Published:2004-04 Issue:4 Volume:48 Page:1413-1415
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Stone Chris¹,Ait-Khaled Mounir²,Craig Charles¹,Griffin Philip¹,Tisdale Margaret¹

Affiliation:

1. International Clinical Virology, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY

2. Clinical Development and Medical Affairs, GlaxoSmithKline, Greenford, Middlesex, United Kingdom

Abstract

ABSTRACT Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.48.4.1413-1415.2004

Reference27 articles.

1. Ait-Khaled, M., R. Lanier, N. Richards, C. Stone, P. Griffin, D. M. Gibb, and A. S. Walker, C. Craig, A. E. Loeliger, and M. Tisdale. 2002. Zidovudine appears to prevent selection of K65R and L74V mutations normally selected by abacavir mono- or combination therapies not containing zidovudine. Antiviral Ther.7(Suppl. 1):S141.

2. Ait-Khaled, M., C. Stone, G. Amphlett, B. Clotet, S. Staszewski, C. Katlama, M. Tisdale, and the C. N. A. International Study Team. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS16:1686-1689.

3. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

4. In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β- d -Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine

5. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments;Antiviral Research;2024-10

2. Comprehensive Database of HIV Mutations Selected During Antiretroviral in Vitro Passage Experiments;2024

3. Avoiding Drug Resistance in HIV Reverse Transcriptase;Chemical Reviews;2021-01-28

4. Gambaran Kasus Mutasi Terkait Resistensi Antiretroviral pada orang dengan HIV-AIDS (ODHA) di Tiga Kabupaten/Kota di Provinsi Papua;Buletin Penelitian Kesehatan;2018-12-06

5. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial;AIDS;2018-10-23